Thrivent Financial for Lutherans Has $78.04 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thrivent Financial for Lutherans cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 624,888 shares of the biotechnology company’s stock after selling 19,787 shares during the period. Thrivent Financial for Lutherans’ holdings in Sarepta Therapeutics were worth $78,042,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky acquired a new position in Sarepta Therapeutics during the second quarter worth $4,771,000. Simplify Asset Management Inc. raised its position in Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after acquiring an additional 88,474 shares in the last quarter. Securian Asset Management Inc. acquired a new stake in Sarepta Therapeutics in the second quarter valued at $1,187,000. Finally, Natixis Advisors LLC bought a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $1,918,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Down 4.2 %

Shares of NASDAQ SRPT opened at $104.54 on Monday. The stock has a market capitalization of $9.99 billion, a P/E ratio of 83.63 and a beta of 0.81. The stock’s fifty day moving average is $123.72 and its 200 day moving average is $132.38. Sarepta Therapeutics, Inc. has a 52 week low of $78.67 and a 52 week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insiders Place Their Bets

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird cut their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, November 7th. Guggenheim lifted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. StockNews.com upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.